If you had paused on Embecta in late 2025, wondering whether steady diabetes-device cash flows and analyst price targets justified a position, the past year has delivered a harsh answer. Investors who held Embecta over the past year are down 53.6%, including dividends. With lawsuits now alleging misleading guidance and weak pen needle demand, the real question is which assumptions about earnings visibility and product resilience were already sitting in plain sight back on 6 November...
If you had backed Embecta on 19 October 2025 and simply held on, the experience would have been brutal. Holding Embecta over the past year would have meant a 54.5% loss, including dividends. At the start, bullish and bearish analysts were arguing over modest revenue shrinkage, margin expansion into the mid teens, and a future P/E between 7.4x and 4.7x. So what did that original investment case miss about pen needle reliance, GLP-1 partnerships and margin durability? The move put Embecta in...
PARSIPPANY, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events: Wells Fargo 2026 Healthcare ConferenceManagement will host one-on-one investor meetings on Wednesday, September 9, 2026, at the Encore Boston Harbor Hotel in Everett, Boston, MA.J.P. Morgan 4th Annu
This is the newest page. Registered accounts read further back.